Pulmatrix (PULM) 10-Q 7 Aug 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 05, 2020
Cover [Abstract]
Entity Registrant Name	Pulmatrix, Inc.
Entity Central Index Key	0001574235
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		32,592,668
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 27,255	$ 23,440
Accounts receivable	353	7,200
Prepaid expenses and other current assets	1,448	777
Total current assets	29,056	31,417
Property and equipment, net	277	270
Operating lease right-of-use asset	1,958	630
Long-term restricted cash	204	204
Goodwill	3,577	3,577
Total assets	35,072	36,098
Current liabilities:
Accounts payable	291	600
Accrued expenses	3,445	2,514
Operating lease liability	861	675
Deferred revenue	10,039	13,411
Total current liabilities	14,636	17,200
Operating lease liability, net of current portion	1,184
Deferred revenue, net of current portion	5,367	7,879
Total liabilities	21,187	25,079
Commitments (Note 8)
Stockholders' equity:
Preferred stock, $0.0001 par value - 500,000 authorized and 0 issued and outstanding at June 30, 2020 and December 31, 2019
Common stock, $0.0001 par value - 200,000,000 shares authorized; 25,749,356 and 19,994,560 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively.	3	2
Additional paid-in capital	234,899	226,178
Accumulated deficit	(221,017)	(215,161)
Total stockholders' equity	13,885	11,019
Total liabilities and stockholders' equity	$ 35,072	$ 36,098

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	25,749,356	19,994,560
Common stock, shares outstanding	25,749,356	19,994,560

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Revenues	$ 3,500	$ 4,819	$ 6,262	$ 4,819
Operating expenses
Research and development	3,184	3,164	8,471	5,340
General and administrative	1,490	3,128	3,702	5,115
Impairment of goodwill		6,474		7,268
Total operating expenses	4,674	12,766	12,173	17,723
Loss from operations	(1,174)	(7,947)	(5,911)	(12,904)
Other income (expense)
Interest income	13	102	65	106
Settlement expense				(200)
Other income/(expense), net	(9)	1	(10)	(2)
Net loss	$ (1,170)	$ (7,844)	$ (5,856)	$ (13,000)
Net loss per share, basic and diluted	$ (0.05)	$ (0.41)	$ (0.26)	$ (0.99)
Weighted average shares of common stock used to compute basic and diluted net loss per share	24,376,571	19,216,172	22,423,014	13,114,242

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018		$ 206,409	$ (194,565)	$ 11,844
Balance, shares at Dec. 31, 2018	4,932,723
Adjustment for reverse stock split, shares	2,717
Issuance of common stock, net of issuance costs	$ 1	$ 2,978		$ 2,979
Issuance of common stock, net of issuance costs, shares	2,394,955
Exercise of pre-funded warrants		70		70
Exercise of pre-funded warrants, shares	697,500
Share-based compensation		459		459
Net loss			(5,156)	(5,156)
Balance at Mar. 31, 2019	$ 1	209,916	(199,721)	10,196
Balance, shares at Mar. 31, 2019	8,027,895
Balance at Dec. 31, 2018		206,409	(194,565)	11,844
Balance, shares at Dec. 31, 2018	4,932,723
Net loss				(13,000)
Balance at Jun. 30, 2019	$ 2	225,655	(207,565)	18,092
Balance, shares at Jun. 30, 2019	19,624,560
Balance at Mar. 31, 2019	$ 1	209,916	(199,721)	10,196
Balance, shares at Mar. 31, 2019	8,027,895
Issuance of common stock, net of issuance costs		14,566		14,566
Issuance of common stock, net of issuance costs, shares	3,319,553
Exercise of pre-funded warrants	$ 1	82		83
Exercise of pre-funded warrants, shares	8,277,112
Share-based compensation		1,091		1,091
Net loss			(7,844)	(7,844)
Balance at Jun. 30, 2019	$ 2	225,655	(207,565)	18,092
Balance, shares at Jun. 30, 2019	19,624,560
Balance at Dec. 31, 2019	$ 2	226,178	(215,161)	11,019
Balance, shares at Dec. 31, 2019	19,994,560
Exercise of pre-funded warrants
Exercise of pre-funded warrants, shares	300,000
Exercise of common stock options		21		21
Exercise of common stock options, shares	19,997
Exercise of warrants		239		239
Exercise of warrants, shares	206,747
Share-based compensation		343		343
Net loss			(4,686)	(4,686)
Balance at Mar. 31, 2020	$ 2	226,781	(219,847)	6,936
Balance, shares at Mar. 31, 2020	20,521,304
Balance at Dec. 31, 2019	$ 2	226,178	(215,161)	11,019
Balance, shares at Dec. 31, 2019	19,994,560
Net loss				(5,856)
Balance at Jun. 30, 2020	$ 3	234,899	(221,017)	13,885
Balance, shares at Jun. 30, 2020	25,749,356
Balance at Mar. 31, 2020	$ 2	226,781	(219,847)	6,936
Balance, shares at Mar. 31, 2020	20,521,304
Issuance of common stock, net of issuance costs	$ 1	7,313		7,314
Issuance of common stock, net of issuance costs, shares	4,787,553
Exercise of common stock options		3		3
Exercise of common stock options, shares	2,500
Exercise of warrants		536		536
Exercise of warrants, shares	437,999
Share-based compensation		266		266
Net loss			(1,170)	(1,170)
Balance at Jun. 30, 2020	$ 3	$ 234,899	$ (221,017)	$ 13,885
Balance, shares at Jun. 30, 2020	25,749,356

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net loss	$ (5,856)	$ (13,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	103	95
Amortization of operating lease right-of-use asset	359	286
Share-based compensation	609	1,550
Impairment of goodwill		7,268
Loss on disposal of property and equipment		(1)
Changes in operating assets and liabilities:
Accounts receivable	6,847
Prepaid expenses and other current assets	(671)	(397)
Accounts payable	(321)	(640)
Accrued expenses	931	(454)
Operating lease liability	(317)	(297)
Deferred revenue	(5,884)	17,181
Net cash (used in)/provided by operating activities	(4,200)	11,591
Cash flows from investing activities:
Purchases of property and equipment	(98)	(35)
Net cash used in investing activities	(98)	(35)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs	7,314	17,545
Proceeds from exercise of common stock options	24
Proceeds from exercise of warrants	775
Proceeds from exercise of pre-funded warrants		153
Proceeds from Paycheck Protection Program loan	617
Repayment of Paycheck Protection Program loan	(617)
Net cash provided by financing activities	8,113	17,698
Net increase in cash, cash equivalents and restricted cash	3,815	29,254
Cash, cash equivalents and restricted cash - beginning of period	23,644	2,767
Cash, cash equivalents and restricted cash - end of period	27,459	32,021
Supplemental disclosures of non-cash investing and financing information:
Fixed asset purchases in accounts payable	12
Operating lease right-of-use asset obtained in exchange for operating lease obligation	$ 1,687	$ 1,213

Organization

Organization	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	1. Organization Pulmatrix, Inc. (the “Company”) was incorporated in 2013 as a Nevada corporation and converted to a Delaware corporation in September 2013. On June 15, 2015, the Company completed a merger with Pulmatrix Operating Company, changed its name from Ruthigen, Inc. to “Pulmatrix, Inc.” and relocated its corporate headquarters to Lexington, Massachusetts. Pulmatrix, Inc. is a clinical stage biotechnology company focused on the discovery and development of a novel class of inhaled therapeutic products. The Company’s proprietary dry powder delivery platform, iSPERSE™ (inhaled Small Particles Easily Respirable and Emitted), is engineered to deliver small, dense particles with highly efficient dispersibility and delivery to the airways, which can be used with an array of dry powder inhaler technologies and can be formulated with a variety of drug substances. The Company is developing a pipeline of iSPERSE-based therapeutic candidates targeted at prevention and treatment of a range of respiratory and other diseases with significant unmet medical needs.

Summary of Significant Accounti

Summary of Significant Accounting Policies and Recent Accounting Standards	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Recent Accounting Standards	2. Summary of Significant Accounting Policies and Recent Accounting Standards Basis of Presentation Principles of Consolidation The condensed consolidated financial statements of the Company included herein have been prepared, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (the “Annual Report”). In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the six months ended June 30, 2020, are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2020. For further information, refer to the financial statements and footnotes included in the Company’s annual financial statements for the fiscal year ended December 31, 2019, which are included in the Company’s annual report on Form 10-K filed with the SEC on March 26, 2020. Use of Estimates In preparing condensed consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results may differ from these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include revenue recognition, valuing equity securities in share-based payments, estimating the useful lives of depreciable and amortizable assets, interest borrowing rate, valuation allowance against deferred tax assets, goodwill impairment, and estimating the fair value of long-lived assets to assess whether impairment charges may apply. Concentrations of Credit Risk and Off-Balance Sheet Arrangements Cash is a financial instrument that potentially subjects the Company to concentrations of credit risk. For all periods presented, substantially all of the Company’s cash was deposited in an account at a single financial institution that management believes is creditworthy. The Company is exposed to credit risk in the event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits. The Company has not incurred any losses to date. We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors. Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents consist of cash, checking accounts and money market accounts. The following table provides a reconciliation of cash, cash equivalents and restricted cash as reported in the condensed consolidated balance sheets that sum to the total of the same amounts in the statement of cash flows. Six months ended June 30 2020 2019 Cash and cash equivalents $ 27,255 $ 31,817 Restricted cash 204 204 Total cash, cash equivalents and restricted cash $ 27,459 $ 32,021 Goodwill Goodwill represents the difference between the consideration transferred and the fair value of the net assets acquired, and liabilities assumed under the acquisition method of accounting for push-down accounting. Goodwill is not amortized but is evaluated for impairment within the Company’s single reporting unit on an annual basis during the fourth quarter, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the Company’s reporting unit below its carrying amount. When performing the impairment assessment, the accounting standard for testing goodwill for impairment permits a company to first assess the qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the goodwill is impaired. If the Company believes, as a result of the qualitative assessment, that it is more likely than not that the fair value of goodwill is impaired, the Company then must perform a quantitative analysis to determine if the carrying value of the reporting entity exceeds its fair value. The impact of the novel coronavirus (“COVID-19”) pandemic was considered in the Company’s qualitative assessment. Currently, there has not been a significant impact on the carrying value of the Company, but this factor will continue to be evaluated. Recently Adopted Accounting Standards In August 2018, the FASB issued ASU 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	6 Months Ended
	Jun. 30, 2020
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Expenses and Other Current Assets	3. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following: At June 30, 2020 At December 31, 2019 Prepaid insurance $ 569 $ 202 Prepaid clinical trials 633 322 Prepaid other 209 221 Deferred operating costs 37 32 Total prepaid and other current assets $ 1,448 $ 777

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2020
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	4. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: At June 30, 2020 At December 31, 2019 Accrued vacation $ 122 $ 42 Accrued wages and incentive 476 527 Accrued clinical & consulting 2,700 1,820 Accrued legal & patent 70 85 Accrued other expenses 77 40 Total accrued expenses $ 3,445 $ 2,514

Common Stock

Common Stock	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Common Stock	5. Common Stock Registered Direct Offering On April 20, 2020, the Company sold 4,787,553 shares at $1.671 per share, pursuant to a securities purchase agreement, dated as of April 16, 2020, by and among the Company and certain institutional investors, for gross proceeds of approximately $8,000 prior to deducting fees and expenses of approximately $686. In a concurrent private placement, the Company issued warrants to purchase an aggregate of up to 4,787,553 shares of its common stock to investors with an exercise price of $1.55 per share and an expiration date of April 20, 2022. In addition, the Company issued warrants to purchase up to 311,191 shares of its common stock to the designees of the placement agent with an exercise price of $2.0888 per share and an expiration date of April 20, 2022. The investor and placement agent warrants have a fair value of approximately $0.64 and $0.54 per share, respectively. Exercise of Warrants During the three months ended June 30, 2020 and 2019, the Company issued 437,999 and 8,277,112 shares of common stock, respectively, upon exercise of warrants to purchase 524,353 and 8,277,112 shares of common stock, respectively. The Company collected proceeds of $536 and $83 upon the exercise of these warrants during the three months ended June 30, 2020 and 2019, respectively. During the six months ended June 30, 2020 and 2019, the Company issued 944,746 and 8,974,612 shares of common stock, respectively, upon exercise of warrants to purchase 1,147,184 and 8,974,612 shares of common stock, respectively. The Company collected proceeds of $775 and $153 upon the exercise of these warrants during the six months ended June 30, 2020 and 2019, respectively. Exercise of Stock Options During the three and six months ended June 30, 2020, stock options to buy 2,500 and 22,497 shares were exercised, respectively, and the Company collected proceeds of $3 and $24, respectively.

Warrants

Warrants	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Warrants	6. Warrants A rollforward of the common stock warrants outstanding at June 30, 2020 is as follows. Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding December 31, 2019 18,953,195 $ 3.55 4.17 $ — Warrants issued 5,098,744 $ 1.58 Warrants exercised (847,184 ) $ (1.09 ) Pre-funded warrants exercised (300,000 ) $ (0.01 ) Warrants expired (2,515 ) $ (83.50 ) Outstanding June 30, 2020 22,902,240 $ 3.23 3.20 $ 5,711 The following represents a summary of the warrants outstanding at each of the dates identified: Number of Shares Underlying Warrants For the Period Ended June 30, Issue Date Classification Exercise Price Expiration Date 2020 2019 April 20, 2020 Equity $ 1.55 April 20, 2022 4,787,553 — April 20, 2020 Equity $ 2.0888 April 20, 2022 311,191 — April 8, 2019 Equity $ 0.01 — — 670,000 April 8, 2019 Equity $ 1.35 April 8, 2024 11,692,518 12,266,665 April 8, 2019 Equity $ 1.6875 April 3, 2024 797,334 797,334 February 12, 2019 Equity $ 1.8313 February 7, 2024 110,922 110,922 February 12, 2019 Equity $ 1.34 August 12, 2024 1,433,447 1,706,484 February 04, 2019 Equity $ 2.125 January 30, 2024 34,605 34,605 January 31, 2019 Equity $ 2.125 January 26, 2024 10,151 10,151 December 3, 2018 Equity $ 3.90 June 3, 2024 937,500 937,500 April 3, 2018 Equity $ 7.50 April 3, 2023 2,350,011 2,350,011 April 4, 2018 Equity $ 7.50 April 4, 2023 115,000 115,000 August 31, 2015 Equity $ 118.00 August 31, 2020 3,000 3,000 June 15, 2015 Equity $ 75.50 Five years after milestone achievement 319,008 319,008 June 15, 2015 Equity $ 83.50 June 16, 2020 — 2,515 Total Outstanding 22,902,240 19,323,195

Share-Based Compensation

Share-Based Compensation	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Share-Based Compensation	7. Share-Based Compensation The Company sponsors the Pulmatrix, Inc. 2013 Employee, Director and Consultant Equity Incentive Plan (the “2013 Plan). As of June 30, 2020, the 2013 Plan provides for the grant of up to 4,060,000 shares of common stock, of which 1,011,381 shares remain available for future grant. In addition, the Company has two legacy plans: The Pulmatrix Operating’s 2013 Employee, Director and Consultant Equity Incentive Plan (the “Original 2013 Plan”) and Pulmatrix Operating’s 2003 Employee, Director, and Consultant Stock Plan (the “2003 Plan”). As of June 30, 2020, a total of 8,627 shares of common stock may be delivered under options outstanding under the Original 2013 Plan and the 2003 Plan, however no additional awards may be granted under the Original 2013 Plan or the 2003 Plan. Stock Options During the three months ended June 30, 2020, the Company granted 105,000 options to employees and directors. The awards vest over four years, expire ten years from the grant date and on the date of the grant have a fair value of $117. During the six months ended June 30, 2020, the Company granted 2,249,104 options to employees, directors, and consultants. The awards vest over four years, expire ten years from the grant date and on the date of grant have a fair value of $2,615. During the three and six months ended June 30, 2019, the Company granted 651,600 options to employees and directors. The awards vest over four years, expire ten years from the grant date and on the date of the grant have a fair value of $456. The following table summarizes stock option activity for the six months ended June 30, 2020: Number of Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding — December 31, 2019 900,003 $ 11.63 8.52 $ — Granted 2,249,104 $ 1.53 Exercised (22,497 ) $ 1.06 Forfeited or expired (146,178 ) $ 27.27 Outstanding — June 30, 2020 2,980,432 $ 3.32 9.21 $ 727 Exercisable — June 30, 2020 637,993 $ 9.55 8.50 $ 134 The estimated fair values of employee stock options granted during the three months and six months ended June 30, 2020 and 2019, were determined on the date of grant using the Black-Scholes option-pricing model with the following assumptions: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Expected option life (years) 6.03 6.02 5.92 6.02 Risk-free interest rate 0.45 % 2.22 % 1.62 % 2.22 % Expected volatility 94.40 % 74.14 % 93.90 % 74.14 % Expected dividend yield 0 % 0 % 0 % 0 % The risk-free interest rate was obtained from U.S. Treasury rates for the applicable periods. The Company’s expected volatility was based upon the average of the historical volatility for industry peers and its own volatility. The expected life of the Company’s options was determined using the simplified method as a result of limited historical data regarding the Company’s activity. The dividend yield considers that the Company has not historically paid dividends and does not expect to pay dividends in the foreseeable future. As of June 30, 2020, there was $2,711 of unrecognized stock-based compensation expense related to unvested stock options granted under the Company’s stock award plans. This expense is expected to be recognized over a weighted-average period of approximately 3.0 years. The following table presents total stock-based compensation expense for the three and six months ended June 30, 2020 and 2019: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Research and development $ 49 $ 18 $ 96 $ 67 General and administrative 217 1,073 513 1,483 Total share-based compensation expense $ 266 $ 1,091 $ 609 $ 1,550

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Research and Development Activities The Company contracts with various other organizations to conduct research and development activities. As of June 30, 2020, the Company had aggregate commitments to pay approximately $4,701 remaining on these contracts. The scope of the services under contracts for research and development activities may be modified and the contracts, subject to certain conditions, may generally be cancelled by the Company upon written notice. In some instances, the contracts, subject to certain conditions, may be cancelled by the third party. Operating Leases The Company has limited leasing activities as a lessee and are primarily related to its corporate headquarters located at 99 Hayden Avenue, Suite 390, Lexington, Massachusetts. The Company currently leases approximately 22 thousand square feet of office and lab space in Lexington, Massachusetts under a lease that expires on December 31, 2020. On April 23, 2020, an extension to the Company’s operating lease for office and lab space was signed between the Company and 99 Hayden LLC. The extension to the original lease executed on May 31, 2007, has a base rent of $1,194 which is adjusted annually by 3%, and will expire on June 30, 2022. The lease provides for base rent, and the Company is responsible for real estate taxes, maintenance, and other operating expenses applicable to the leased premises. Operating lease liabilities and corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as prepaid rent. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rates, which are the rates incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. To estimate the Company’s specific incremental borrowing rates over the respective lease terms, a comparable market yield curve consistent with the Company’s credit quality was used. As of June 30, 2020, the weighted average incremental borrowing rate and the weighted average remaining lease term for the operating leases held by the Company were 5.23% and 2 years, respectively. The components of lease expense for the Company as of June 30, 2020 were as follows: For the three months ended For the six months ended June 30, June 30, 2020 2019 2020 2019 Lease Cost Fixed lease cost $ 228 $ 164 $ 391 $ 327 Variable lease cost 99 90 218 187 Total lease cost $ 327 $ 254 $ 609 $ 514 Maturities of lease liabilities due under these lease agreements as of June 30, 2020 are as follows: Operating Leases Maturity of lease liabilities: 2020 (excluding the six months ended June 30, 2020) $ 349 2021 1,194 2022 (lease expiration on June 30, 2022) 615 Total lease payments 2,158 Less imputed interest (114 ) Total operating lease liabilities $ 2,044 SBA Loan On April 10, 2020, the Company received a loan of $617 through the Paycheck Protection Program. Administered through the U.S. Small Business Administration, the loan was made possible through the Coronavirus Aid, Relief and Economic Security Act. On April 28, 2020, the Company repaid the loan in full.

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Net Loss Per Share	9. Net Loss Per Share The Company computes basic and diluted net loss per share using a methodology that gives effect to the impact of outstanding participating securities (the “two-class method”). As the three and six months ended June 30, 2020 and 2019, respectively, resulted in net losses attributable to common stockholders, there is no income allocation required under the two-class method or dilution attributed to weighted average shares outstanding in the calculation of diluted net loss per share. The following potentially dilutive securities outstanding prior to the use of the treasury stock method have been excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive. As of June 30, 2020 2019 Options to purchase common stock 2,980,432 1,427,045 Warrants to purchase common stock 22,902,240 18,653,195 Total 25,882,672 20,080,240

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Events On July 10, 2020, the joint steering committee established by the Company and Cipla Technologies, LLC, with whom the Company entered into a development and commercialization agreement on April 15, 2019 for the development and commercialization of Pulmazole, terminated the Company’s Phase 2 clinical study of Pulmazole. On July 9, 2020, the Company entered into letter agreements with certain existing accredited investors to exercise certain existing and outstanding warrants (“Existing Warrants”) to purchase up to an aggregate of 10,085,741 shares of the Company’s common stock at the existing exercise price per share of $1.35. The Existing Warrants were issued in an underwritten public offering pursuant to a registration statement on Form S-1 (File No. 333-230395) and an additional registration statement on Form S-1 filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (File No. 333-230714) that was consummated in April 2019. In consideration for the exercise of the Existing Warrants for cash, we agreed to issue the exercising holders new unregistered warrants to purchase up to an aggregate of 10,085,741 shares of common stock at an exercise price of $1.80 per share and with an exercise period of five years from the closing date. The gross proceeds to the Company from the exercise are expected to be approximately $13,616, prior to deducting placement agent fees and offering expenses. In addition, we agreed to issue placement agents 655,573 unregistered warrants at an exercise price of $2.25 and with an exercise period of five years from the closing date. On July 8, 2020, 270,000 warrants issued in April 2019 were exercised. The Company collected $365 and issued 270,000 shares of common stock.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Recent Accounting Standards (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation
Principles of Consolidation	Principles of Consolidation The condensed consolidated financial statements of the Company included herein have been prepared, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (the “Annual Report”). In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the six months ended June 30, 2020, are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2020. For further information, refer to the financial statements and footnotes included in the Company’s annual financial statements for the fiscal year ended December 31, 2019, which are included in the Company’s annual report on Form 10-K filed with the SEC on March 26, 2020.
Use of Estimates	Use of Estimates In preparing condensed consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results may differ from these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include revenue recognition, valuing equity securities in share-based payments, estimating the useful lives of depreciable and amortizable assets, interest borrowing rate, valuation allowance against deferred tax assets, goodwill impairment, and estimating the fair value of long-lived assets to assess whether impairment charges may apply.
Concentrations of Credit Risk and Off-Balance Sheet Arrangements	Concentrations of Credit Risk and Off-Balance Sheet Arrangements Cash is a financial instrument that potentially subjects the Company to concentrations of credit risk. For all periods presented, substantially all of the Company’s cash was deposited in an account at a single financial institution that management believes is creditworthy. The Company is exposed to credit risk in the event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits. The Company has not incurred any losses to date. We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents consist of cash, checking accounts and money market accounts. The following table provides a reconciliation of cash, cash equivalents and restricted cash as reported in the condensed consolidated balance sheets that sum to the total of the same amounts in the statement of cash flows. Six months ended June 30 2020 2019 Cash and cash equivalents $ 27,255 $ 31,817 Restricted cash 204 204 Total cash, cash equivalents and restricted cash $ 27,459 $ 32,021
Goodwill	Goodwill Goodwill represents the difference between the consideration transferred and the fair value of the net assets acquired, and liabilities assumed under the acquisition method of accounting for push-down accounting. Goodwill is not amortized but is evaluated for impairment within the Company’s single reporting unit on an annual basis during the fourth quarter, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the Company’s reporting unit below its carrying amount. When performing the impairment assessment, the accounting standard for testing goodwill for impairment permits a company to first assess the qualitative factors to determine whether the existence of events and circumstances indicates that it is more likely than not that the goodwill is impaired. If the Company believes, as a result of the qualitative assessment, that it is more likely than not that the fair value of goodwill is impaired, the Company then must perform a quantitative analysis to determine if the carrying value of the reporting entity exceeds its fair value. The impact of the novel coronavirus (“COVID-19”) pandemic was considered in the Company’s qualitative assessment. Currently, there has not been a significant impact on the carrying value of the Company, but this factor will continue to be evaluated.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In August 2018, the FASB issued ASU 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement

Summary of Significant Accoun_3

Summary of Significant Accounting Policies and Recent Accounting Standards (Tables)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash as reported in the condensed consolidated balance sheets that sum to the total of the same amounts in the statement of cash flows. Six months ended June 30 2020 2019 Cash and cash equivalents $ 27,255 $ 31,817 Restricted cash 204 204 Total cash, cash equivalents and restricted cash $ 27,459 $ 32,021

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2020
Prepaid Expense and Other Assets, Current [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following: At June 30, 2020 At December 31, 2019 Prepaid insurance $ 569 $ 202 Prepaid clinical trials 633 322 Prepaid other 209 221 Deferred operating costs 37 32 Total prepaid and other current assets $ 1,448 $ 777

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2020
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses and other current liabilities consisted of the following: At June 30, 2020 At December 31, 2019 Accrued vacation $ 122 $ 42 Accrued wages and incentive 476 527 Accrued clinical & consulting 2,700 1,820 Accrued legal & patent 70 85 Accrued other expenses 77 40 Total accrued expenses $ 3,445 $ 2,514

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Schedule of Rollforward of Common Stock Warrants Outstanding	A rollforward of the common stock warrants outstanding at June 30, 2020 is as follows. Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding December 31, 2019 18,953,195 $ 3.55 4.17 $ — Warrants issued 5,098,744 $ 1.58 Warrants exercised (847,184 ) $ (1.09 ) Pre-funded warrants exercised (300,000 ) $ (0.01 ) Warrants expired (2,515 ) $ (83.50 ) Outstanding June 30, 2020 22,902,240 $ 3.23 3.20 $ 5,711
Schedule of Warrants Outstanding	The following represents a summary of the warrants outstanding at each of the dates identified: Number of Shares Underlying Warrants For the Period Ended June 30, Issue Date Classification Exercise Price Expiration Date 2020 2019 April 20, 2020 Equity $ 1.55 April 20, 2022 4,787,553 — April 20, 2020 Equity $ 2.0888 April 20, 2022 311,191 — April 8, 2019 Equity $ 0.01 — — 670,000 April 8, 2019 Equity $ 1.35 April 8, 2024 11,692,518 12,266,665 April 8, 2019 Equity $ 1.6875 April 3, 2024 797,334 797,334 February 12, 2019 Equity $ 1.8313 February 7, 2024 110,922 110,922 February 12, 2019 Equity $ 1.34 August 12, 2024 1,433,447 1,706,484 February 04, 2019 Equity $ 2.125 January 30, 2024 34,605 34,605 January 31, 2019 Equity $ 2.125 January 26, 2024 10,151 10,151 December 3, 2018 Equity $ 3.90 June 3, 2024 937,500 937,500 April 3, 2018 Equity $ 7.50 April 3, 2023 2,350,011 2,350,011 April 4, 2018 Equity $ 7.50 April 4, 2023 115,000 115,000 August 31, 2015 Equity $ 118.00 August 31, 2020 3,000 3,000 June 15, 2015 Equity $ 75.50 Five years after milestone achievement 319,008 319,008 June 15, 2015 Equity $ 83.50 June 16, 2020 — 2,515 Total Outstanding 22,902,240 19,323,195

Share-Based Compensation (Table

Share-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Summary of Stock Option Activity	The following table summarizes stock option activity for the six months ended June 30, 2020: Number of Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding — December 31, 2019 900,003 $ 11.63 8.52 $ — Granted 2,249,104 $ 1.53 Exercised (22,497 ) $ 1.06 Forfeited or expired (146,178 ) $ 27.27 Outstanding — June 30, 2020 2,980,432 $ 3.32 9.21 $ 727 Exercisable — June 30, 2020 637,993 $ 9.55 8.50 $ 134
Schedule of Calculation of Fair Value Assumptions	The estimated fair values of employee stock options granted during the three months and six months ended June 30, 2020 and 2019, were determined on the date of grant using the Black-Scholes option-pricing model with the following assumptions: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Expected option life (years) 6.03 6.02 5.92 6.02 Risk-free interest rate 0.45 % 2.22 % 1.62 % 2.22 % Expected volatility 94.40 % 74.14 % 93.90 % 74.14 % Expected dividend yield 0 % 0 % 0 % 0 %
Schedule of Stock-Based Compensation Expense	The following table presents total stock-based compensation expense for the three and six months ended June 30, 2020 and 2019: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Research and development $ 49 $ 18 $ 96 $ 67 General and administrative 217 1,073 513 1,483 Total share-based compensation expense $ 266 $ 1,091 $ 609 $ 1,550

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Schedule of Components of Lease Expense	The components of lease expense for the Company as of June 30, 2020 were as follows: For the three months ended For the six months ended June 30, June 30, 2020 2019 2020 2019 Lease Cost Fixed lease cost $ 228 $ 164 $ 391 $ 327 Variable lease cost 99 90 218 187 Total lease cost $ 327 $ 254 $ 609 $ 514
Schedule of Maturities of Lease Liabilities	Maturities of lease liabilities due under these lease agreements as of June 30, 2020 are as follows: Operating Leases Maturity of lease liabilities: 2020 (excluding the six months ended June 30, 2020) $ 349 2021 1,194 2022 (lease expiration on June 30, 2022) 615 Total lease payments 2,158 Less imputed interest (114 ) Total operating lease liabilities $ 2,044

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Schedule of Computation of Anti-Dilutive Weighted-Average Shares Outstanding	The following potentially dilutive securities outstanding prior to the use of the treasury stock method have been excluded from the computation of diluted weighted-average shares outstanding, as they would be anti-dilutive. As of June 30, 2020 2019 Options to purchase common stock 2,980,432 1,427,045 Warrants to purchase common stock 22,902,240 18,653,195 Total 25,882,672 20,080,240

Summary of Significant Accoun_4

Summary of Significant Accounting Policies and Recent Accounting Standards - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019
Accounting Policies [Abstract]
Cash and cash equivalents	$ 27,255	$ 23,440	$ 31,817
Restricted cash	204		204
Total cash, cash equivalents and restricted cash	$ 27,459		$ 32,021

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid insurance	$ 569	$ 202
Prepaid clinical trials	633	322
Prepaid other	209	221
Deferred operating costs	37	32
Total prepaid and other current assets	$ 1,448	$ 777

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued vacation	$ 122	$ 42
Accrued wages and incentive	476	527
Accrued clinical & consulting	2,700	1,820
Accrued legal & patent	70	85
Accrued other expenses	77	40
Total accrued expenses	$ 3,445	$ 2,514

Common Stock (Details Narrative

Common Stock (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Apr. 20, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Warrants to purchase shares of common stock		22,902,240	19,323,195	22,902,240	19,323,195
Proceeds from warrants exercised				$ 775
Proceeds from stock options				$ 24
Stock Option [Member]
Number of stock options shares exercised		2,500		22,497
Proceeds from stock options		$ 3		$ 24
Warrants [Member]
Warrants to purchase shares of common stock		524,353	8,277,112	524,353	8,277,112
Proceeds from warrants exercised		$ 536	$ 83
Warrants [Member] | Investors [Member]
Warrants to purchase shares of common stock	4,787,553
Warrant exercise price per share	$ 1.55
Warrant expiration date	Apr. 20, 2022
Warrants [Member] | Placement Agents [Member]
Warrants to purchase shares of common stock	311,191
Warrant exercise price per share	$ 2.0888
Warrant expiration date	Apr. 20, 2022
Warrants [Member] | Investors [Member]
Warrant exercise price per share	$ 0.64
Warrants [Member] | Placement Agents [Member]
Warrant exercise price per share	$ 0.54
Common Stock [Member]
Number of common stock shares issued		437,999	8,277,112	944,746	8,974,612
Warrants One [Member]
Warrants to purchase shares of common stock		1,147,184	8,974,612	1,147,184	8,974,612
Proceeds from warrants exercised				$ 775	$ 153
Registered Direct Offering [Member]
Common stock shares sold	4,787,553
Sale of stock price per share	$ 1.671
Proceeds from sale of stock	$ 8,000
Deducting fees and expenses	$ 686

Warrants - Schedule of Rollforw

Warrants - Schedule of Rollforward of Common Stock Warrants Outstanding (Details) - Warrants [Member] $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)$ / sharesshares
Number of Warrants, Outstanding, Beginning Balance | shares	18,953,195
Number of Warrants, Warrants issued | shares	5,098,744
Number of Warrants, Warrants exercised | shares	(847,184)
Number of Warrants, Pre-funded warrants exercised | shares	(300,000)
Number of Warrants, Warrants expired | shares	(2,515)
Number of Warrants, Outstanding, Ending Balance | shares	22,902,240
Weighted Average Exercise Price, Outstanding, Beginning balance | $ / shares	$ 3.55
Weighted Average Exercise Price, Warrants issued | $ / shares	1.58
Weighted Average Exercise Price, Warrants exercised | $ / shares	(1.09)
Weighted Average Exercise Price, Pre-funded warrants exercised | $ / shares	(0.01)
Weighted Average Exercise Price, Warrants expired | $ / shares	(83.50)
Weighted Average Exercise Price, Outstanding, Ending balance | $ / shares	$ 3.23
Weighted Average Remaining Contractual Term (Years), Outstanding, Beginning Balance	4 years 2 months 1 day
Weighted Average Remaining Contractual Term (Years), Outstanding, Ending balance	3 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding, Beginning balance | $
Aggregate Intrinsic Value, Outstanding, Ending balance | $	$ 5,711

Warrants - Schedule of Warrants

Warrants - Schedule of Warrants Outstanding (Details) - $ / shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Number of Shares Underlying Warrants	22,902,240	19,323,195
Warrant One [Member]
Warrants, Issue Date	Apr. 20, 2020
Warrants, Classification	Equity
Warrants, Exercise Price	$ 1.55
Warrants, Expiration Date	Apr. 20, 2022
Number of Shares Underlying Warrants	4,787,553
Warrant Two [Member]
Warrants, Issue Date	Apr. 20, 2020
Warrants, Classification	Equity
Warrants, Exercise Price	$ 2.0888
Warrants, Expiration Date	Apr. 20, 2022
Number of Shares Underlying Warrants	311,191
Warrant Three [Member]
Warrants, Issue Date	Apr. 8, 2019
Warrants, Classification	Equity
Warrants, Exercise Price	$ 0.01
Number of Shares Underlying Warrants		670,000
Warrant Four [Member]
Warrants, Issue Date	Apr. 8, 2019
Warrants, Classification	Equity
Warrants, Exercise Price	$ 1.35
Warrants, Expiration Date	Apr. 8, 2024
Number of Shares Underlying Warrants	11,692,518	12,266,665
Warrant Five [Member]
Warrants, Issue Date	Apr. 8, 2019
Warrants, Classification	Equity
Warrants, Exercise Price	$ 1.6875
Warrants, Expiration Date	Apr. 3, 2024
Number of Shares Underlying Warrants	797,334	797,334
Warrant Six [Member]
Warrants, Issue Date	Feb. 12, 2019
Warrants, Classification	Equity
Warrants, Exercise Price	$ 1.8313
Warrants, Expiration Date	Feb. 7, 2024
Number of Shares Underlying Warrants	110,922	110,922
Warrant Seven [Member]
Warrants, Issue Date	Feb. 12, 2019
Warrants, Classification	Equity
Warrants, Exercise Price	$ 1.34
Warrants, Expiration Date	Aug. 12, 2024
Number of Shares Underlying Warrants	1,433,447	1,706,484
Warrant Eight [Member]
Warrants, Issue Date	Feb. 4, 2019
Warrants, Classification	Equity
Warrants, Exercise Price	$ 2.125
Warrants, Expiration Date	Jan. 30, 2024
Number of Shares Underlying Warrants	34,605	34,605
Warrant Nine [Member]
Warrants, Issue Date	Jan. 31, 2019
Warrants, Classification	Equity
Warrants, Exercise Price	$ 2.125
Warrants, Expiration Date	Jan. 26, 2024
Number of Shares Underlying Warrants	10,151	10,151
Warrant Ten [Member]
Warrants, Issue Date	Dec. 3, 2018
Warrants, Classification	Equity
Warrants, Exercise Price	$ 3.90
Warrants, Expiration Date	Jun. 3, 2024
Number of Shares Underlying Warrants	937,500	937,500
Warrant Eleven [Member]
Warrants, Issue Date	Apr. 3, 2018
Warrants, Classification	Equity
Warrants, Exercise Price	$ 7.50
Warrants, Expiration Date	Apr. 3, 2023
Number of Shares Underlying Warrants	2,350,011	2,350,011
Warrant Twelve [Member]
Warrants, Issue Date	Apr. 4, 2018
Warrants, Classification	Equity
Warrants, Exercise Price	$ 7.50
Warrants, Expiration Date	Apr. 4, 2023
Number of Shares Underlying Warrants	115,000	115,000
Warrant Thirteen [Member]
Warrants, Issue Date	Aug. 31, 2015
Warrants, Classification	Equity
Warrants, Exercise Price	$ 118
Warrants, Expiration Date	Aug. 31, 2020
Number of Shares Underlying Warrants	3,000	3,000
Warrant Fourteen [Member]
Warrants, Issue Date	Jun. 15, 2015
Warrants, Classification	Equity
Warrants, Exercise Price	$ 75.50
Warrants, Expiration Date, Description	Five years after milestone achievement
Number of Shares Underlying Warrants	319,008	319,008
Warrant Fifteen [Member]
Warrants, Issue Date	Jun. 15, 2015
Warrants, Classification	Equity
Warrants, Exercise Price	$ 83.50
Warrants, Expiration Date	Jun. 16, 2020
Number of Shares Underlying Warrants		2,515

Share-Based Compensation (Detai

Share-Based Compensation (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Employees and Directors [Member]
Number of shares provides for grant	105,000	651,600		651,600
Award vesting period	4 years	4 years		4 years
Award expiration term	10 years	10 years		10 years
Fair value of granted shares awarded	$ 117	$ 456		$ 456
Employees Directors and Consultants [Member]
Number of shares provides for grant			2,249,104
Award vesting period			4 years
Award expiration term			10 years
Fair value of granted shares awarded			$ 2,615
2013 Employee, Director and Consultant Equity Incentive Plan [Member]
Number of shares authorized to grant	4,060,000		4,060,000
Shares remain available for future grant	1,011,381		1,011,381
Number of common stock shares outstanding	8,627		8,627
Stock Award Plan [Member]
Unrecognized stock-based compensation expenses	$ 2,711		$ 2,711
Weighted-average period of unrecognized stock-based compensation expense			3 years

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Stock Option Activity (Details) - Stock Option [Member] $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)$ / sharesshares
Number of Options, Outstanding, Beginning Balance | shares	900,003
Number of Options, Granted | shares	2,249,104
Number of Options, Exercised | shares	(22,497)
Number of Options, Forfeited or expired | shares	(146,178)
Number of Options, Outstanding, Ending Balance | shares	2,980,432
Number of Options, Outstanding, Exercisable | shares	637,993
Weighted Average Exercise Price, Outstanding, Beginning Balance | $ / shares	$ 11.63
Weighted Average Exercise Price, Granted | $ / shares	1.53
Weighted Average Exercise Price, Exercised | $ / shares	1.06
Weighted Average Exercise Price, Forfeited or Expired | $ / shares	27.27
Weighted Average Exercise Price, Outstanding, Ending Balance | $ / shares	3.32
Weighted Average Exercise Price, Outstanding, Exercisable | $ / shares	$ 9.55
Weighted Average Remaining Contractual Term (Years), Outstanding, Beginning Balance	8 years 6 months 7 days
Weighted Average Remaining Contractual Term (Years), Outstanding, Ending balance	9 years 2 months 16 days
Weighted Average Remaining Contractual Term (Years), Outstanding, Exercisable	8 years 6 months
Aggregate Intrinsic Value, Outstanding, Beginning Balance | $
Aggregate Intrinsic Value, Outstanding, Ending Balance | $	727
Aggregate Intrinsic Value, Outstanding, Exercisable | $	$ 134

Share-Based Compensation - Sche

Share-Based Compensation - Schedule of Calculation of Fair Value Assumptions (Details) - Employee Stock Option [Member]	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected option life (years)	6 years 11 days	6 years 7 days	5 years 11 months 1 day	6 years 7 days
Risk-free interest rate	0.45%	2.22%	1.62%	2.22%
Expected volatility	94.40%	74.14%	93.90%	74.14%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%

Share-Based Compensation - Sc_2

Share-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share- based compensation expense	$ 266	$ 1,091	$ 609	$ 1,550
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share- based compensation expense	49	18	96	67
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share- based compensation expense	$ 217	$ 1,073	$ 513	$ 1,483

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) $ in Thousands	Apr. 23, 2020USD ($)	Jun. 30, 2020USD ($)ft²	Apr. 10, 2020USD ($)
Payments for commitments		$ 4,701
Area of lease | ft²		22,000
Operating lease expiration date		Dec. 31, 2020
Weighted average incremental borrowing rate		5.23%
Weighted average remaining lease term		2 years
Paycheck Protection Program [Member]
Loan amount			$ 617
Hayden LLC [Member]
Operating lease expiration date	Jun. 30, 2022
Payments for rent	$ 1,194
Rent percentage	3.00%

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Fixed lease cost	$ 228	$ 164	$ 391	$ 327
Variable lease cost	99	90	218	187
Total lease cost	$ 327	$ 254	$ 609	$ 514

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Maturities of Lease Liabilities (Details) $ in Thousands	Jun. 30, 2020USD ($)
Commitments and Contingencies Disclosure [Abstract]
2020 (excluding the six months ended June 30, 2020)	$ 349
2021	1,194
2022 (lease expiration on June 30, 2022)	615
Total lease payments	2,158
Less imputed interest	(114)
Total operating lease liabilities	$ 2,044

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Computation of Anti-Dilutive Weighted-Average Shares Outstanding (Details) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Potential dilutive securities excluded from computation of diluted net loss per common share	25,882,672	20,080,240
Options to Purchase Common Stock [Member]
Potential dilutive securities excluded from computation of diluted net loss per common share	2,980,432	1,427,045
Warrants to Purchase Common Stock [Member]
Potential dilutive securities excluded from computation of diluted net loss per common share	22,902,240	18,653,195

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Jul. 09, 2020	Jul. 08, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Apr. 20, 2020
Warrants to purchase shares of common stock			22,902,240	19,323,195	22,902,240	19,323,195
Proceeds from exercise of warrants					$ 775
Warrants [Member]
Warrants to purchase shares of common stock			524,353	8,277,112	524,353	8,277,112
Proceeds from exercise of warrants			$ 536	$ 83
Warrants [Member] | Placement Agents [Member]
Warrants to purchase shares of common stock							311,191
Warrant exercise price per share							$ 2.0888
Subsequent Event [Member] | Existing Warrants [Member]
Warrants to purchase shares of common stock	10,085,741	270,000
Proceeds from exercise of warrants		$ 365
Warrant exercise price per share	$ 1.35
Number of common stock shares issued		270,000
Subsequent Event [Member] | Warrants [Member]
Warrants to purchase shares of common stock	10,085,741
Proceeds from exercise of warrants	$ 13,616
Warrant exercise price per share	$ 1.80
Warrants term	5 years
Subsequent Event [Member] | Warrants [Member] | Placement Agents [Member]
Warrants to purchase shares of common stock	655,573
Warrant exercise price per share	$ 2.25
Warrants term	5 years